This CPB is revised to state that bortezomib is considered medically necessary for second-line treatment of persons with relapsed or refractory angioimmunoblastic T-cell lymphoma, anaplastic large cell lymphoma, or enteropathy-associated T-cell lymphoma who are not candidates for high-dose chemotherapy and autologous stem cell transplantation. This CPB has been revised to state that bortezomib is considered experimental and investigational for autoimmune disorders including autoimmune hemolytic anemia.